Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;12(2):172-210.
doi: 10.22088/IJMCM.BUMS.12.2.172.

Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging

Fakhrossadat Farvadi  1 , Fatemeh Hashemi  2 , Azadeh Amini  3 , Molood Alsadat Vakilinezhad  4 , Mohammad Javad Raee  1
Affiliations
Review

Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging

Fakhrossadat Farvadi et al. Int J Mol Cell Med. 2023.

Abstract

The increasing prevalence of Alzheimer's disease (AD) has led to a health crisis. According to official statistics, more than 55 million people globally have AD or other types of dementia, making it the sixth leading cause of death. It is still difficult to diagnose AD and there is no definitive diagnosis yet; post-mortem autopsy is still the only definite method. Moreover, clinical manifestations occur very late in the course of disease progression; therefore, profound irreversible changes have already occurred when the disease manifests. Studies have shown that in the preclinical stage of AD, changes in some biomarkers are measurable prior to any neurological damage or other symptoms. Hence, creating a reliable, fast, and affordable method capable of detecting AD in early stage has attracted the most attention. Seeking clinically applicable, inexpensive, less invasive, and much more easily accessible biomarkers for early diagnosis of AD, blood-based biomarkers (BBBs) seem to be an ideal option. This review is an inclusive report of BBBs that have been shown to be altered in the course of AD progression. The aim of this report is to provide comprehensive insight into the research status of early detection of AD based on BBBs.

Keywords: Alzheimer’s disease; blood-based biomarker; early diagnosis; multiplexing.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Alzheimer's disease biomarkers
See this image and copyright information in PMC

References

    1. Dementia: World Health Organization. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia .
    1. Fearing MA, Bigler ED, Norton M, et al. Autopsy-confirmed Alzheimer's disease versus clinically diagnosed Alzheimer's disease in the Cache County Study on Memory and Aging: a comparison of quantitative MRI and neuropsychological findings. J Clin Exp Neuropsychol. 2007;29:553–60. - PubMed
    1. Dementia As. Medical Tests: Alzheimer's Association. Available from: https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests.
    1. Knopman DS. Alzheimer disease biomarkers and insights into mild cognitive impairment. Neurology. 2013;80:978–80. - PubMed
    1. Burnham SC, Faux NG, Wilson W, et al. A blood-based predictor for neocortical Abeta burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry. 2014;19:519–26. - PubMed

LinkOut - more resources